About The Study: In patients with symptomatic rheumatic heart disease, digoxin reduced the risk of a composite of all-cause death or new-onset or worsening heart failure, with little risk of toxicity. This study is being published to coincide with the European Society of Cardiology Heart Failure 2026 Congress.
Corresponding Author: To contact the corresponding author, Ganesan Karthikeyan, MD, DM, MSc, email karthik2010@gmail.com.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.7335)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7335?guestAccessKey=d4c39490-13af-453e-a188-9ccefd58b4a9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051026
Journal
JAMA